Cargando…

Noncanonical EZH2 drives retinoic acid resistance of variant acute promyelocytic leukemias

Cancer cell heterogeneity is a major driver of therapy resistance. To characterize resistant cells and their vulnerabilities, we studied the PLZF-RARA variant of acute promyelocytic leukemia, resistant to retinoic acid (RA), using single-cell multiomics. We uncovered transcriptional and chromatin he...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poplineau, Mathilde, Platet, Nadine, Mazuel, Adrien, Hérault, Léonard, N’Guyen, Lia, Koide, Shuhei, Nakajima-Takagi, Yaeko, Kuribayashi, Wakako, Carbuccia, Nadine, Haboub, Loreen, Vernerey, Julien, Oshima, Motohiko, Birnbaum, Daniel, Iwama, Atsushi, Duprez, Estelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Myeloid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653050/ https://www.ncbi.nlm.nih.gov/pubmed/35984905 http://dx.doi.org/10.1182/blood.2022015668

Ejemplares similares

Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia
por: Balasundaram, Nithya, et al.
Publicado: (2022)

Author Correction to: Single-cell RNA-seq reveals a concomitant delay in differentiation and cell cycle of aged hematopoietic stem cells
por: Hérault, Léonard, et al.
Publicado: (2021)

Single-cell RNA-seq reveals a concomitant delay in differentiation and cell cycle of aged hematopoietic stem cells
por: Hérault, Léonard, et al.
Publicado: (2021)

Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2022)

Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia
por: Epstein-Peterson, Zachary D., et al.
Publicado: (2022)

Recurrent noncoding somatic and germline WT1 variants converge to disrupt MYB binding in acute promyelocytic leukemia
por: Song, Huan, et al.
Publicado: (2022)

PLZF limits enhancer activity during hematopoietic progenitor aging
por: Poplineau, Mathilde, et al.
Publicado: (2019)

HMGA2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2/M inhibition
por: Moison, Céline, et al.
Publicado: (2022)

Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia
por: Niu, Xiaojia, et al.
Publicado: (2021)

Calcitonin receptor‐like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML
por: Angenendt, Linus, et al.
Publicado: (2021)

Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies
por: Stengel, Anna, et al.
Publicado: (2021)

A geno-clinical decision model for the diagnosis of myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2021)

Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia
por: Wakita, Satoshi, et al.
Publicado: (2022)

Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression
por: Stratmann, Svea, et al.
Publicado: (2022)

An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia
por: Ragaini, Simone, et al.
Publicado: (2022)

Transcription factor MEF2D is required for the maintenance of MLL-rearranged acute myeloid leukemia
por: Zhao, Lianzhong, et al.
Publicado: (2021)

A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes
por: Wang, Yu-Hung, et al.
Publicado: (2021)

A clinically applicable gene expression–based score predicts resistance to induction treatment in acute myeloid leukemia
por: Moser, Christian, et al.
Publicado: (2021)

The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML
por: Heikamp, Emily B., et al.
Publicado: (2022)

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia
por: Goswami, Swagata, et al.
Publicado: (2022)

CAMK2G is identified as a novel therapeutic target for myelofibrosis
por: Miyauchi, Masashi, et al.
Publicado: (2022)

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
por: Middeke, Jan M., et al.
Publicado: (2022)

Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia
por: Fobare, Sydney, et al.
Publicado: (2022)

Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy
por: Versluis, Jurjen, et al.
Publicado: (2022)

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
por: Weinberg, Olga K., et al.
Publicado: (2022)

Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition
por: Maslah, Nabih, et al.
Publicado: (2022)

Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome
por: Iijima, Mayuko, et al.
Publicado: (2022)

Historical expectations with DNA methyltransferase inhibitor monotherapy in MDS: when is combination therapy truly “promising”?
por: Brunner, Andrew M., et al.
Publicado: (2022)

Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML
por: Martelli, Maria Paola, et al.
Publicado: (2021)

ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
por: Buccisano, Francesco, et al.
Publicado: (2022)

Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML
por: Ramaswamy, Kavitha, et al.
Publicado: (2022)

SORT1/LAMP2-mediated extracellular vesicle secretion and cell adhesion are linked to lenalidomide resistance in multiple myeloma
por: Yamamoto, Tomofumi, et al.
Publicado: (2022)

The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11
por: Lafage-Pochitaloff, Marina, et al.
Publicado: (2022)

Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition
por: Kong, Tim, et al.
Publicado: (2022)

Coping strategies in patients with acute myeloid leukemia
por: Amonoo, Hermioni L., et al.
Publicado: (2022)

Genome-wide screening identifies cell-cycle control as a synthetic lethal pathway with SRSF2(P95H) mutation
por: Xu, Jane Jialu, et al.
Publicado: (2022)

Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses
por: Knudsen, Trine Alma, et al.
Publicado: (2022)

CombiFlow: combinatorial AML-specific plasma membrane expression profiles allow longitudinal tracking of clones
por: Houtsma, Roos, et al.
Publicado: (2022)

Simple and robust methylation test for risk stratification of patients with juvenile myelomonocytic leukemia
por: Kitazawa, Hironobu, et al.
Publicado: (2021)

t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity
por: Mueller, Sarah B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l159jleasr3scb5h9meippphs8